introduct
infecti
mononucleosi
im
common
viral
infect
typic
caus
fever
pharyng
lymphadenopathi
young
patient
epsteinbarr
viru
ebv
common
caus
im
follow
cytomegaloviru
cmv
given
serolog
test
associ
limit
regard
accuraci
avail
time
receiv
result
clinic
differenti
base
symptom
sign
basic
test
would
use
evalu
whether
clinic
find
could
use
differenti
ebvim
cmvim
method
singlecent
retrospect
casecontrol
studi
evalu
patient
serolog
confirm
ebvim
cmvim
compar
patient
symptom
physic
find
blood
count
serum
biomark
creat
three
regress
model
model
symptom
sign
model
model
plu
sonograph
hepatosplenomegali
blood
count
model
model
plu
hepatobiliari
biomark
result
among
patient
ebvim
patient
cmvim
median
age
year
patient
male
median
age
year
older
cmvim
group
p
median
interv
onset
visit
day
longer
cmvim
group
p
logist
regress
reveal
ebvim
predict
younger
age
short
onsettovisit
interv
lymphadenopathi
tonsillar
white
coat
hepatosplenomegali
atyp
lymphocytosi
elev
lactat
dehydrogenas
gammaglutamyl
transferas
regress
model
area
curv
conclus
histori
physic
find
especi
use
atyp
lymphocytosi
sonograph
hepatosplenomegali
help
physician
differenti
ebvim
cmvim
infecti
mononucleosi
im
common
selflimit
viral
infect
typic
affect
juvenil
patient
present
classic
triad
fever
pharyng
lymphadenopathi
case
im
caus
epsteinbarr
viru
ebv
second
common
caus
agent
cytomegaloviru
cmv
caus
case
condit
must
consid
differenti
diagnosi
includ
toxoplasmosi
human
herp
infect
human
herp
infect
adenoviru
infect
rubella
herp
simplex
viru
hsv
infect
influenzaparainfluenza
viru
infect
rhinoviru
infect
coronaviru
infect
acut
human
immunodefici
viru
hiv
infect
rel
im
caus
ebv
ebvim
im
caus
cmv
cmvim
reportedli
affect
patient
year
older
present
milder
lymphadenopathi
pharyng
frequent
seriou
hepat
thrombocytopenia
howev
review
conclud
ebvim
cmvim
nearli
indistinguish
context
serolog
examin
use
identifi
caus
agent
heterophil
antibodi
test
hat
wide
avail
rel
rapid
test
limit
low
sensit
earli
phase
young
patient
although
combin
antibodi
specif
ebv
cmv
accur
even
specif
antibodi
sever
limit
first
serolog
examin
use
initi
diagnosi
requir
sever
day
obtain
result
limit
applic
retrospect
confirm
second
serolog
examin
expens
wide
avail
especi
import
issu
primari
care
set
rural
area
third
despit
combin
ebvspecif
antibodi
test
high
accuraci
infrequ
produc
inaccur
result
fals
neg
crossreact
cmvim
furthermor
question
regard
accuraci
cmvigm
diagnos
primari
acut
cmv
infect
thu
would
help
primari
care
physician
differenti
ebvim
cmvim
base
symptom
clinic
sign
readili
avail
laboratori
data
complet
blood
count
cbc
howev
awar
studi
directli
compar
clinic
characterist
ebvim
cmvim
studi
limit
small
size
absenc
multivari
analys
therefor
present
studi
aim
determin
whether
clinic
find
could
use
differenti
ebvim
cmvim
serolog
confirm
could
obtain
singlecent
retrospect
casecontrol
casecas
studi
evalu
medic
record
immunocompet
patient
serolog
confirm
ebvim
cmvim
toho
univers
medic
center
omori
hospit
bed
locat
southern
part
tokyo
japan
center
ethic
committe
approv
studi
retrospect
protocol
patient
includ
year
old
receiv
inpati
outpati
treatment
clinic
evid
serolog
confirm
ebvim
cmvim
gener
medicin
emerg
care
depart
januari
decemb
serolog
confirm
ebvim
base
result
ebv
nuclear
antigen
ebna
plu
result
viral
capsid
antigen
igm
vcaigm
measur
use
fluoresc
antibodi
fa
techniqu
serolog
confirm
cmvim
base
result
cmvigm
measur
use
enzym
immunoassay
test
perform
srl
tokyo
japan
regard
initi
dilut
concentr
offici
provid
manufactur
fujirebio
inc
tokyo
japan
examin
kit
cutoff
valu
ebna
vcaigm
due
methodolog
difficulti
involv
set
clear
cutoff
valu
test
use
fa
techniqu
discuss
issu
staff
member
srl
cmvigm
cutoff
valu
set
base
valu
provid
manufactur
denka
seiken
co
ltd
tokyo
japan
although
valu
borderlin
select
lowest
valu
rang
obtain
sensit
result
intend
categor
patient
diabet
mellitu
liver
cirrhosi
endstag
renal
diseas
cancer
receiv
immunosuppress
glucocorticoid
immunocompromis
exclus
pregnant
women
intent
exclud
doctor
charg
patient
includ
resid
doctor
complet
postgradu
year
least
experienc
attend
physician
laboratori
data
collect
first
visit
patient
record
search
collect
data
first
visit
regard
sex
age
interv
onset
first
visit
fever
sore
throat
cervic
lymphadenopathi
headach
abdomin
pain
cough
facial
edema
rash
throat
red
tonsillar
white
coat
abdomin
tender
sonograph
hepatosplenomegali
leukocyt
count
atyp
lymphocyt
platelet
count
serum
creactiv
protein
crp
serum
total
bilirubin
serum
aspart
aminotransferas
ast
serum
alanin
transaminas
alt
serum
lactat
dehydrogenas
ldh
serum
alkalin
phosphatas
alp
serum
gammaglutamyl
transferas
ggt
pharyng
identifi
base
sore
throat
andor
throat
red
classic
triad
defin
fever
pharyng
lymphadenopathi
fever
defin
bodi
temperatur
c
hepatosplenomegali
identifi
base
ultrasoundbas
confirm
hepatomegali
andor
splenomegali
leukocytosi
defin
leukocyt
count
thrombocytopenia
defin
platelet
count
analys
continu
variabl
categor
age
year
year
year
atyp
lymphocyt
alt
iul
iul
iul
ldh
iul
iul
iul
alp
iul
iul
iul
ggt
iul
iul
iul
cutoff
valu
age
leukocytosi
thrombocytopenia
atyp
lymphocytosi
alt
level
select
base
previou
relev
studi
distribut
data
use
origin
categori
ldh
alp
ggt
level
base
previou
studi
distribut
data
univari
analys
perform
compar
characterist
patient
ebvim
cmvim
categor
variabl
compar
use
chisquar
test
wilcoxon
ranksum
test
use
continu
variabl
variabl
skew
distribut
logist
regress
analysi
subsequ
perform
base
result
univari
analys
differenti
abil
histori
physic
find
h
p
cbc
ultrasoundconfirm
hepatosplenomegali
hepatobiliari
biomark
test
use
three
model
model
h
p
factor
model
model
plu
hepatosplenomegali
cbc
model
model
plu
hepatobiliari
maker
howev
given
rel
small
sampl
size
limit
number
explanatori
variabl
carri
forward
factor
signific
previou
regress
model
eg
signific
h
p
variabl
model
includ
model
thu
model
ultim
includ
age
interv
onset
visit
lymphadenopathi
pharyng
headach
facial
edema
tonsillar
white
coat
abdomin
tender
classic
triad
model
ultim
includ
age
interv
onset
visit
lymphadenopathi
tonsillar
white
coat
hepatosplenomegali
leukocytosi
atyp
lymphocyt
percentag
thrombocytopenia
model
ultim
includ
age
lymphadenopathi
tonsillar
white
coat
hepatosplenomegali
leukocytosi
atyp
lymphocyt
percentag
alt
alp
ggt
evalu
multicollinear
examin
varianc
inflat
factor
regress
model
although
sex
bodi
temperatur
import
factor
includ
classic
triad
omit
model
signific
differ
detect
univari
analys
also
omit
ast
base
multicollinear
alt
alt
gener
consid
specif
liver
biomark
receiv
oper
characterist
roc
curv
creat
differenti
abil
three
regress
model
compar
use
method
delong
et
al
analys
perform
use
stataic
softwar
version
stata
corp
usa
elig
patient
includ
patient
ebvim
patient
cmvim
median
age
year
patient
male
pregnant
women
absent
patient
subsequ
underw
serolog
examin
concurr
differenti
diagnosi
im
includ
test
toxoplasmosi
adenoviru
rubella
hsv
influenza
parainfluenza
rhinoviru
coronaviru
acut
hiv
infect
patient
eventu
exclud
due
immunocompromis
statu
patient
diabet
mellitu
liver
cirrhosi
endstag
renal
diseas
cancer
receiv
immunosuppress
glucocorticoid
patient
characterist
result
univari
analys
shown
tabl
univari
analys
reveal
median
age
year
older
cmvim
group
p
median
interv
onset
visit
day
longer
cmvim
group
p
headach
symptom
frequent
cmvim
group
ebvim
group
like
exhibit
pharyng
classic
triad
tonsillar
white
coat
cervic
lymphadenopathi
abdomin
tender
hepatosplenomegali
leukocytosi
atyp
lymphocytosi
elev
hepatobiliari
enzym
platelet
count
significantli
lower
ebvim
group
p
although
median
platelet
count
still
tabl
model
reveal
lower
odd
ratio
ebvim
older
age
longer
interv
first
visit
patient
contrast
significantli
higher
or
ebvim
observ
patient
cervic
lymphadenopathi
tonsillar
white
coat
none
factor
statist
signific
model
tabl
model
reveal
lower
ebvim
older
age
well
higher
or
patient
cervic
lymphadenopathi
hepatosplenomegali
leukocytosi
atyp
lymphocytosi
interv
onset
visit
tonsillar
white
coat
thrombocytopenia
signific
factor
model
tabl
model
reveal
lower
ebvim
older
age
well
higher
or
patient
cervic
lymphadenopathi
tonsillar
white
coat
mildtomoder
elev
atyp
lymphocytosi
ldh
iul
ggt
iul
extrem
elev
atyp
lymphocyt
ldh
ggt
well
hepatosplenomegali
leukocytosi
alt
elev
alp
elev
signific
factor
model
tabl
mean
varianc
inflat
factor
model
model
model
method
delong
et
al
reveal
auc
valu
model
model
model
model
consid
highli
accur
base
auc
valu
fig
singlecent
retrospect
casecontrol
casecas
studi
evalu
whether
wide
avail
clinic
find
laboratori
test
result
could
use
differenti
ebvim
cmvim
univari
multivari
analys
use
creat
test
variou
diagnost
model
reveal
ebvim
significantli
predict
younger
age
shorter
interv
onset
hospit
visit
cervic
lymphadenopathi
tonsillar
white
coat
hepatosplenomegali
atyp
lymphocytosi
moder
elev
ldh
gtt
present
studi
reveal
patient
cmvim
notic
higher
previous
report
proport
three
factor
may
explain
discrep
rel
previou
studi
clinic
practic
first
limit
patient
serolog
confirm
ebvim
cmvim
case
ie
exclud
differenti
diagnos
im
may
produc
higher
preval
cmvim
studi
second
differ
patient
ethnic
age
may
relev
previou
studi
evalu
nonasian
pediatr
patient
third
differ
serolog
test
ie
hat
vs
ebvspecif
antibodi
may
explain
discrep
issu
context
serolog
diagnosi
discuss
follow
paragraph
characterist
serolog
test
relev
differ
preval
cmvim
signific
find
hat
ebvspecif
antibodi
test
use
diagnos
ebvim
hat
convent
method
base
fact
ebvim
patient
transient
develop
antibodi
react
erythrocyt
antigen
nonhuman
mammal
sheep
hors
addit
hat
wide
use
serolog
support
diagnosi
ebvim
inexpens
rapid
wide
avail
howev
hat
provid
neg
result
ebvim
patient
first
week
infect
posit
result
ebvim
patient
year
old
thu
given
low
sensit
hat
longer
recommend
diagnosi
ebvim
wide
avail
japan
given
cmvim
refer
differenti
diagnosi
heterophil
antibodi
neg
mononucleosi
previou
review
articl
previou
studi
probabl
differenti
ebvim
cmvim
base
hat
result
howev
use
specif
antibodi
ebv
cmv
instead
heterophil
antibodi
differ
serolog
test
method
may
explain
differ
preval
cmvim
current
recommend
use
ebvspecif
antibodi
diagnos
ebvim
better
diagnost
abil
hat
combin
use
vcaigm
vcaigg
ebna
provid
sensit
specif
although
sensit
vcaigm
first
week
furthermor
crossreact
cmvim
report
patient
thu
even
ebvspecif
antibodi
may
produc
inaccur
result
reliabl
cmvigm
diagnos
primari
acut
cmv
infect
also
problemat
poor
correl
report
sever
commerci
test
kit
falseposit
result
due
persist
elev
reactiv
addit
technolog
issu
specif
antibodi
test
ebv
cmv
expens
difficult
use
primari
care
set
requir
sever
day
obtain
result
thu
although
ebvspecif
antibodi
test
good
tool
diagnos
ebvim
limit
highlight
import
excess
reli
serolog
test
estim
appropri
pretest
probabl
base
symptom
sign
rapidli
avail
test
result
serolog
result
receiv
result
indic
patient
cmvim
longer
interv
onset
visit
previou
studi
also
reveal
cmvim
associ
prolong
fever
elev
hepatobiliari
biomark
postdiagnost
cours
thu
clinic
characterist
cmvim
hospit
visit
appear
milder
persist
longer
characterist
ebvim
possibl
sever
symptom
ebvim
pharyng
pain
lymphadenopathi
may
motiv
patient
seek
medic
treatment
sooner
patient
cmvim
among
classic
symptom
sign
pharyng
tonsillar
white
coat
cervic
lymphadenopathi
hepatosplenomegali
significantli
associ
ebvim
univari
analysi
furthermor
younger
age
lymphadenopathi
tonsillar
white
coat
signific
predictor
ebvim
regress
model
facial
edema
report
specif
symptom
ebvim
caus
disturb
orbit
lymphat
drainag
due
nasopharyng
inflamm
cervic
lymphaden
present
studi
facial
edema
observ
ebvim
case
vs
p
although
signific
factor
regress
model
nevertheless
facial
edema
ebvim
may
wellknown
common
symptom
may
underdiagnos
abdomin
pain
tender
also
report
case
ebvim
like
relat
remark
distent
liver
spleen
acalcul
cholecyst
splenic
infarct
find
also
reveal
abdomin
tender
significantli
common
among
ebvim
case
vs
p
although
factor
also
signific
regress
model
hepatosplenomegali
leukocytosi
signific
predictor
ebvim
model
model
context
hepatosplenomegali
wellknown
sign
ebvim
although
leukocytosi
thrombocytopenia
may
predictor
cmvim
although
previou
studi
report
inconsist
result
find
indic
thrombocytopenia
sever
albeit
significantli
ebvim
case
although
atyp
lymphocytosi
assum
nonspecif
reaction
caus
variou
immun
disturb
found
significantli
predict
ebvim
regress
model
result
compat
find
previous
studi
analys
includ
multivari
regress
model
reveal
significantli
higher
hepatobiliari
marker
ebvim
case
similar
result
previou
studi
hepatobiliari
marker
ebvim
cmvim
case
reveal
significantli
higher
hepatobiliari
biomark
ebvim
patient
howev
recent
studi
indic
differ
signific
logist
regress
analys
reveal
mildtomoder
elev
ggt
ldh
independ
predictor
ebvim
find
may
use
evalu
hepatobiliari
biomark
im
patient
studi
compar
hepatobiliari
marker
patient
ebvim
cmvim
time
first
visit
aim
demonstr
clinic
differ
ebvim
cmvim
recogniz
serolog
confirm
howev
time
test
import
interpret
reportedli
elev
recoveri
hepatobiliari
marker
take
longer
cmvim
case
ebvim
case
thu
precis
interpret
interv
onset
test
consid
case
comparison
three
regress
model
fig
show
model
use
h
p
factor
could
precis
differenti
ebvim
cmvim
auc
model
ad
hepatosplenomegali
cbc
improv
differenti
abil
auc
howev
addit
hepatobiliari
biomark
improv
auc
valu
model
thu
physician
may
abl
accur
differenti
ebvim
cmvim
use
h
p
factor
without
wide
avail
test
result
eg
cbc
hepatosplenomegali
detect
rather
reli
serolog
examin
present
studi
sever
limit
first
sampl
size
small
patient
cmvim
case
rel
larg
number
explanatori
factor
might
affect
odd
ratio
estim
variabl
logist
regress
model
especi
model
nevertheless
studi
larger
previou
similar
studi
recogn
small
sampl
size
could
allow
us
estim
precis
odd
ratio
valu
howev
perform
logist
regress
specif
clinic
laboratori
find
aim
clarifi
contribut
clinic
sign
laboratori
find
independ
second
studi
potenti
risk
interact
among
covari
model
clinic
symptom
lymphadenopathi
hepatosplenomegali
laboratori
data
lymphocytosi
may
deep
correl
etiolog
although
exclud
appar
multicollinear
evalu
varianc
inflat
factor
possibl
interact
neg
impact
statist
reliabl
address
third
insuffici
exclus
differenti
diagnos
im
could
reduc
reliabl
result
particip
serolog
confirm
ebvim
cmvim
underw
test
serolog
exclus
differenti
diagnos
im
includ
infect
toxoplasmosi
adenoviru
rubella
hsv
influenza
parainfluenza
rhinoviru
coronaviru
acut
hiv
infect
although
simultan
mix
infect
ebv
cmv
imcaus
infecti
agent
rare
routin
serolog
exclus
might
improv
reliabl
studi
find
given
studi
perform
metropolitan
citi
tokyo
studi
find
may
influenc
potenti
confound
undiagnos
concurr
acut
hiv
infect
result
cautious
appli
patient
clinic
im
patient
group
present
studi
limit
patient
serolog
diagnos
ebvim
cmvim
patient
clinic
diagnos
im
fourth
could
access
data
regard
import
factor
eg
histori
present
ill
common
symptom
fatigu
nausea
vomit
specif
site
swollen
lymph
node
fifth
varianc
clinic
expertis
doctor
charg
case
may
affect
result
physic
examin
reliabl
studi
sixth
consid
lymphocyt
count
elect
use
atyp
lymphocytosi
specif
signific
measur
lymphocyt
count
possibl
approach
limit
applic
find
automat
lymphocyt
count
use
flow
cytometri
often
readili
avail
atyp
lymphocyt
count
clinic
practic
seventh
consid
distribut
data
cutoff
valu
present
studi
previous
defin
valu
could
consid
arbitrari
studi
need
address
limit
although
believ
studi
provid
import
preliminari
evid
h
p
factor
clinic
characterist
may
use
diagnosi
ebvim
conclus
retrospect
casecontrol
studi
reveal
younger
age
shorter
interv
onset
hospit
visit
cervic
lymphadenopathi
tonsillar
white
coat
hepatosplenomegali
atyp
lymphocytosi
moder
elev
ldh
gtt
could
use
differenti
ebvim
cmvim
find
impli
evalu
h
p
factor
especi
combin
cbc
ultrasonographi
data
may
allow
physician
differenti
ebvim
cmvim
receiv
serolog
confirm
none
icmj
statement
author
meet
icmj
authorship
criteria
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
